BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30089916)

  • 1. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M
    Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 17-gene stemness score for rapid determination of risk in acute leukaemia.
    Ng SW; Mitchell A; Kennedy JA; Chen WC; McLeod J; Ibrahimova N; Arruda A; Popescu A; Gupta V; Schimmer AD; Schuh AC; Yee KW; Bullinger L; Herold T; Görlich D; Büchner T; Hiddemann W; Berdel WE; Wörmann B; Cheok M; Preudhomme C; Dombret H; Metzeler K; Buske C; Löwenberg B; Valk PJ; Zandstra PW; Minden MD; Dick JE; Wang JC
    Nature; 2016 Dec; 540(7633):433-437. PubMed ID: 27926740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
    Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
    JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
    Elsayed AH; Rafiee R; Cao X; Raimondi S; Downing JR; Ribeiro R; Fan Y; Gruber TA; Baker S; Klco J; Rubnitz JE; Pounds S; Lamba JK
    Leukemia; 2020 Mar; 34(3):735-745. PubMed ID: 31645648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia.
    Ng SWK; Murphy T; King I; Zhang T; Mah M; Lu Z; Stickle N; Ibrahimova N; Arruda A; Mitchell A; Mai M; He R; Madala BS; Viswanatha DS; Dick JE; Chan S; Virtanen C; Minden MD; Mercer T; Stockley T; Wang JCY
    Blood Adv; 2022 Feb; 6(3):1064-1073. PubMed ID: 34872104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia.
    Huang BJ; Smith JL; Farrar JE; Wang YC; Umeda M; Ries RE; Leonti AR; Crowgey E; Furlan SN; Tarlock K; Armendariz M; Liu Y; Shaw TI; Wei L; Gerbing RB; Cooper TM; Gamis AS; Aplenc R; Kolb EA; Rubnitz J; Ma J; Klco JM; Ma X; Alonzo TA; Triche T; Meshinchi S
    Nat Commun; 2022 Sep; 13(1):5487. PubMed ID: 36123353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
    Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
    J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel 85-Gene Expression Signature Predicts Unfavorable Prognosis in Acute Myeloid Leukemia.
    Lai Y; Sheng L; Wang J; Zhou M; OuYang G
    Technol Cancer Res Treat; 2021; 20():15330338211004933. PubMed ID: 33784904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.
    Vasseur L; Fenwarth L; Lambert J; de Botton S; Figeac M; Villenet C; Heiblig M; Dumas PY; Récher C; Berthon C; Lemasle E; Lebon D; Lambert J; Terré C; Celli-Lebras K; Dombret H; Preudhomme C; Cheok M; Itzykson R; Duployez N
    Blood Adv; 2023 Aug; 7(15):4024-4034. PubMed ID: 37205853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct prognostic values of Annexin family members expression in acute myeloid leukemia.
    Niu Y; Yang X; Chen Y; Jin X; Xie Y; Tang Y; Li L; Liu S; Guo Y; Li X; Duan L; Wang H
    Clin Transl Oncol; 2019 Sep; 21(9):1186-1196. PubMed ID: 30694461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 4-microRNA signature for survival prognosis in pediatric and adolescent acute myeloid leukemia.
    Zhu R; Lin W; Zhao W; Fan F; Tang L; Hu Y
    J Cell Biochem; 2019 Mar; 120(3):3958-3968. PubMed ID: 30242879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
    Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
    Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
    Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
    Wu X; Wang H; Deng J; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Nov; 98(11):2485-2496. PubMed ID: 31482295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
    Kandeel EZ; Madney Y; Eldin DN; Shafik NF
    Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.
    Metzeler KH; Maharry K; Kohlschmidt J; Volinia S; Mrózek K; Becker H; Nicolet D; Whitman SP; Mendler JH; Schwind S; Eisfeld AK; Wu YZ; Powell BL; Carter TH; Wetzler M; Kolitz JE; Baer MR; Carroll AJ; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
    Leukemia; 2013 Oct; 27(10):2023-31. PubMed ID: 23765227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.